Inhibikase Therapeutics, Inc.

IKT Healthcare Biotechnology

Inhibikase Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $260,500.00, up 111.1% from fiscal 2022. In the quarter to June 2026, EPS was flat and free cash flow fell 123.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

1.65 0.18 −9.84%
Market cap
$255.4M
P/E
0.0×
Fwd P/E
−2.6×
Dividend yield
—
F-score
3/9
Altman Z
−8.82
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
15.82 30.14 21.70 11.73
Net Debt/EBITDA
7.55 9.55 12.98 6.07
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.07) (0.07) (0.08) (0.12)
Book value per Share
0.88 0.97 1.76 0.81
Free Cash Flow
(12.44) (12.06) (7.52) (10.59)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates